Redeye comments on Embracer’s divestments of selected assets from Saber Interactive, including all a...
Biovica’s sales from clinical use of DiviTum tests are up 350% in Q3 compared with the first half, a...
Yesterday evening, the board of directors announced the appointment of Julian Read as the new CEO of...
Ljummet kvartal med vissa ljusglimtar Gullberg & Jansson levererade en svagare avslutning på året.
Redeye provides a brief comment on Smart Eye's second Interior Sensing deal that it was announced ea...
Redeye retains its Base Case and 2025 forecasts despite the softer short-term outlook in the newly a...
Hjalmar Jernström presents a case reminder for OptiCept Technologies, and comments on the recent new...
Lägre tillväxt men bättre marginal och kassaflöde än väntat, leder till att kassan bör räcka och där...
Aktieanalytiker Örjan Rödén presenterar sin syn på Sensys Gatso Group, ett lönsamt tillväxtbolag med...
- SEK 465m in two orders for Intercom and Vehicle radios.
Omsättningen ökade under Q4 och trots att marknaden är osäker talar mycket för ett starkare 2024.
Redeye is encouraged by Fluoguide delivering on its promises by entering a collaboration in head and...
Redeye comments on today’s news where Freemelt announced its intention to carry out a fully secured ...
Redeye takes a positive stance towards Speqta’s direct share issue despite somewhat lowering its Bas...
Redeye is pleased that Ortoma has received the 510(K) approval from the US FDA regarding the OTS™ Hi...
Redeye comments on Artificial Solutions' Q4 2023 report, which showed a total ARR of SEK63m and a Sa...
Redeye endorses the results from ISAB’s first-in-human clinical study of its PreciseInhale system.
ARR and P&L headline figures known, cash flow and cost items not Timing of guidance upgrade hard to ...
Interview with I-Tech's CFO Magnus Henell Continued growth and profitability in '24 New customer lau...
Redeye reviews the case of Herantis in the wake of progress with clinical candidate HER-096 and H2 r...